Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)
NCT ID: NCT03104478
Last Updated: 2021-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
219 participants
OBSERVATIONAL
2017-05-09
2021-09-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The feasibility and efficiency will be demonstrated by deploying and operating a nation-wide network of dedicated multidisciplinary platforms.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biological samples collection
In addition to collection and characterization of tumor biopsy samples done for diagnosis (standard care), collection of blood samples at study entry for further biological analyses.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A short corticotherapy (prednisone, maximum 7 days) given during pre-phase therapy is allowed.
* Eligible histological subtypes: in particular DLBCL NOS, PMBL, high grade B-cell lymphoma (HGBCL) withMYC and BCL2 and/or BCL6 rearrangements, HGBCL NOSFL grade 3B and untreated transformed low grade NHL.
* ≥ 18 years old, IPI = 0-5
* With available tumor Biopsy (FFPE) that can be sent to RT3 platform at the time of inclusion (or the say after inclusion at the latest).
* Patient that underwent needle core biopsy samples are not excluded if sufficient material is available for molecular and histopathological explorations
Exclusion Criteria
* No signed informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Lymphoma Academic Research Organisation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fabrice Jardin, Pr
Role: PRINCIPAL_INVESTIGATOR
Lymphoma Study Association
Christiane Copie, Pr
Role: PRINCIPAL_INVESTIGATOR
Lymphoma Study Association
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Caen
Caen, , France
Hopital Henri Mondor
Créteil, , France
CHU Le Bocage
Dijon, , France
CH Départemental
La Roche-sur-Yon, , France
CHU Claude Hurriez
Lille, , France
CHU Montpellier
Montpellier, , France
CHU de Nantes
Nantes, , France
Centre Francois Magendie
Pessac, , France
CHU Lyon Sud
Pierre-Bénite, , France
CHU de Poitiers - Hôpital de la Miletrie
Poitiers, , France
Ch Annecy Genevois
Pringy, , France
Centre Henri Becquerel
Rouen, , France
IUCT Oncopôle - CHU de Toulouse
Toulouse, , France
CHU Nancy Brabois
Vandœuvre-lès-Nancy, , France
Institut Gustave Roussy
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RT3
Identifier Type: -
Identifier Source: org_study_id